160 related articles for article (PubMed ID: 22120021)
21. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1989; 4(4):253-8. PubMed ID: 2549487
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic co-operation in beta-cell tumorigenesis.
Pelengaris S; Khan M
Endocr Relat Cancer; 2001 Dec; 8(4):307-14. PubMed ID: 11733227
[TBL] [Abstract][Full Text] [Related]
23. Molecular analyses of liver tumors in c-myc transgenic mice and c-myc and TGF-alpha double transgenic mice.
Ohgaki H; Sanderson ND; Ton P; Thorgeirsson SS
Cancer Lett; 1996 Aug; 106(1):43-9. PubMed ID: 8827045
[TBL] [Abstract][Full Text] [Related]
24. Differential regulation of the clusterin gene by Ha-ras and c-myc oncogenes and during apoptosis.
Klock G; Storch S; Rickert J; Gutacker C; Koch-Brandt C
J Cell Physiol; 1998 Dec; 177(4):593-605. PubMed ID: 10092212
[TBL] [Abstract][Full Text] [Related]
25. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis.
Schmidt T; Karsunky H; Gau E; Zevnik B; Elsässer HP; Möröy T
Oncogene; 1998 Nov; 17(20):2661-7. PubMed ID: 9840930
[TBL] [Abstract][Full Text] [Related]
26. The immunoglobulin heavy chain gene 3' enhancers induce Bcl2 deregulation and lymphomagenesis in murine B cells.
Xiang H; Noonan EJ; Wang J; Duan H; Ma L; Michie S; Boxer LM
Leukemia; 2011 Sep; 25(9):1484-93. PubMed ID: 21606958
[TBL] [Abstract][Full Text] [Related]
27. Oncogene cooperation in lymphocyte transformation: malignant conversion of E mu-myc transgenic pre-B cells in vitro is enhanced by v-H-ras or v-raf but not v-abl.
Alexander WS; Adams JM; Cory S
Mol Cell Biol; 1989 Jan; 9(1):67-73. PubMed ID: 2784537
[TBL] [Abstract][Full Text] [Related]
28. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice.
Langdon WY; Harris AW; Cory S; Adams JM
Cell; 1986 Oct; 47(1):11-8. PubMed ID: 3093082
[TBL] [Abstract][Full Text] [Related]
29. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
[TBL] [Abstract][Full Text] [Related]
30. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
31. Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations.
Alexander WS; Bernard O; Cory S; Adams JM
Oncogene; 1989 May; 4(5):575-81. PubMed ID: 2657573
[TBL] [Abstract][Full Text] [Related]
32. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
33. Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways.
Luo F; Brooks DG; Ye H; Hamoudi R; Poulogiannis G; Patek CE; Winton DJ; Arends MJ
Int J Exp Pathol; 2009 Oct; 90(5):558-74. PubMed ID: 19765110
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 in myeloma/plasmacytoma.
Suematsu S; Matsusaka T; Matsuda T; Hirano T; Kishimoto T
Int Rev Exp Pathol; 1993; 34 Pt A():91-8. PubMed ID: 8454420
[No Abstract] [Full Text] [Related]
35. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
36. Plasmablastic transformation of low-grade CD5+ B-cell lymphoproliferative disorder with MYC gene rearrangements.
Pan Z; Xie Q; Repertinger S; Richendollar BG; Chan WC; Huang Q
Hum Pathol; 2013 Oct; 44(10):2139-48. PubMed ID: 23791008
[TBL] [Abstract][Full Text] [Related]
37. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.
Nussenzweig MC; Schmidt EV; Shaw AC; Sinn E; Campos-Torres J; Mathey-Prevot B; Pattengale PK; Leder P
Nature; 1988 Dec; 336(6198):446-50. PubMed ID: 3143076
[TBL] [Abstract][Full Text] [Related]
38. Ras mediates effector pathways responsible for pre-B cell survival, which is essential for the developmental progression to the late pre-B cell stage.
Nagaoka H; Takahashi Y; Hayashi R; Nakamura T; Ishii K; Matsuda J; Ogura A; Shirakata Y; Karasuyama H; Sudo T; Nishikawa S; Tsubata T; Mizuochi T; Asano T; Sakano H; Takemori T
J Exp Med; 2000 Jul; 192(2):171-82. PubMed ID: 10899904
[TBL] [Abstract][Full Text] [Related]
39. Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice.
Factor V; Oliver AL; Panta GR; Thorgeirsson SS; Sonenshein GE; Arsura M
Hepatology; 2001 Jul; 34(1):32-41. PubMed ID: 11431731
[TBL] [Abstract][Full Text] [Related]
40. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
